#397 What's Next for the ABA Antitrust Law Section? Stability, Balance, and Value
Our Curious AmalgamShow Notes
What's ahead for the ABA Antitrust Law Section in 2026–2027? Section Chair Melanie Aitken and Counsel to the Chair Christina Skinner join Our Curious Amalgam to discuss Melanie's vision for the Section and her priorities for the coming year. Listen to this episode to learn how under Melanie's leadership, the Section plans to double down on its value to members, strengthen its leadership and processes, and remain a home for vigorous debate and a broad range of perspectives across the antitrust community.
With special guests: Melanie Aitken, Chair, ABA Antitrust Law Section and Christina Skinner, Counsel to the Chair, ABA Antitrust Law Section
Hosted by: Anora Wang and Lexi Michaud, Fried Frank
More from Our Curious Amalgam
State-level pre-merger notification requirements are becoming more popular. But what is happening in California? Heather Greenfield, partner at White & Case, joins Jaclyn Phillips and Puja Patel to discuss how California's law fits into an overall notification strategy. Listen to this episode to learn more about what to expect and how to prepare when the law becomes effective on January 1, 2027. With special guest: Heather Greenfield, Partner, White & Case
What does competition and litigation risk look like from inside a company operating at the intersection of financial markets, data, technology, and regulation? Kay Lynn Brumbaugh, Head of Litigation, Group Legal at London Stock Exchange Group plc (LSEG), joins Anora Wang and Matthew Hall to share an in-house perspective on managing disputes in a highly regulated global business. Listen to this episode to learn how issues involving data access, market infrastructure, AI, and overlapping regulatory regimes look from inside the client. With special guest: Kay Lynn Brumbaugh, Head of Litigation, Group Legal, London Stock Exchange Group plc
The Federal 340B Drug Pricing Program has grown from a modest drug discount program into a massive federal program involving pharmaceutical manufacturers, hospitals, pharmacies, insurers, and third-party administrators. But when can similar conduct by participants in this program suggest coordination or raise other competition concerns? Archan Ruparel, economist at Charles River Associates, joins Brian Auricchio and Jaclyn Phillips to discuss economic considerations when evaluating potential antitrust concerns relating to 340B. Listen to this episode to learn more about factors that can help analyze this conduct. With special guest: Archan Ruparel, Charles River Associates
The European Court of Justice's judgment in Google Android is one of the most consequential EU competition law judgments of the last decade. But why is it so important? Thomas Höppner, lawyer at Geradin Partners, joins Matthew Hall and Subrata Bhattacharjee to discuss the key issues raised and their relevance to abuse of dominance cases generally. Listen to this episode to learn more about counterfactual analysis, the relevance of context and the latest on the as-efficient-competitor test and principle. With special guest: Thomas Höppner, partner, Geradin Partners
Larry Buterman is one of the rare antitrust attorneys who has successfully first chaired landmark cases both at the DOJ Antitrust Division and in private practice. In this career profile, co-hosts Derek Jackson and Lexi Michaud ask Larry about the differences and similarities in representing the DOJ versus representing a private party, about Larry's trial war stories (including his cross-examination of a famous athlete), about advice for aspiring litigators, and more. Listen to this episode to learn about the experience of an antitrust trial lawyer and how you might become one too. With special guest: Larry Buterman, Partner, Latham & Watkins LLP